David Hooper Joins Evolution Marketing Research as Senior Director, Research

... BLUE BELL Pa. April 29 2013 /PRNewswire/-...(Logo: a href http://photos.prnewswire.com/prnh/20130429/PH0268...Most recently David served as Director Global Market Information &am... David not only brings to Evolution highly specialized experience in t...

BLUE BELL, Pa., April 29, 2013 /PRNewswire/-- Evolution Marketing Research, a leading supplier of insights and intelligence to the healthcare industry, announces that David Hooper has joined the firm as Senior Director, Research. David leverages more than 13 years of experience leading and managing strategic research and analysis initiatives in the healthcare and pharmaceutical industries to further strengthen Evolution's specialized client services.

Most recently, David served as Director, Global Market Information & Research, at Warner Chilcott, LLC, a global specialty pharmaceutical company. In that role, David designed and led market research initiatives in support of in-line products and business development opportunities, and evaluated and modified data sources and internal reports to strengthen market insights. He implemented a new functional area consisting of market research, market analytics, and forecasting; developed a process and statistical model for brand/market level forecasting; and created tools to more effectively support the company's sales team.

"David not only brings to Evolution highly specialized experience in the pharmaceutical and healthcare industries, but also a clear commitment to improving processes related to research and analysis," said James E. Heasley II , Ph.D., Evolution Principal. "We look forward to sharing his expertise with our clients and continuing to strengthen our marketing research capabilities."

Prior to Warner Chilcott, David spent six years in market research at Merck & Co. and Schering-Plough Corporation. He also has several additional years of experience in other research and analytic roles, including previous global market research consulting experience. He received his B.A. in Psychology from Boston University, and his M.S., in Physiology and Biophysics, from Georgetown University.

About Evolution Marketing ResearchEvolution Marketing Research is a healthcare marketing research firm that provides qualitative and quantitative research, consulting services, project management, advisory board monitoring and other marketing research services to pharmaceutical, biotech and medical device companies all over the world. Company principals John Taenzler , Ph.D., Jim Cummings and James Heasley , Ph.D., who are backed by a seasoned team of analysts and researchers, bring their collective experience to bear on projects at all phases of the product lifecycle, from opportunity and licensing assessments, to product crafting in support of phase III clinical trial design, to development of the commercial platform for developmental and in-line products. To learn more, visit www.evolved-mr.com.

Contact: Karen Murray 215-850-4645

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

(Date:12/8/2016)... CA (PRWEB) , ... December 08, 2016 , ... Lajollacooks4u, ... was a banner year for team building events, new program offerings and company expansion. ... it expanded earlier this year to include groups of over 30 people. Ever since, ...

(Date:12/8/2016)... Biotheranostics today announced that new data will ... Cancer Index (BCI) in identifying which patients with ... for disease recurrence and might benefit from extended ... advancing the understanding of the value of BCI ... inform decisions related to patient treatment. These data ...

(Date:11/21/2016)... Lithuania , Nov. 21, 2016 ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...

(Date:11/15/2016)... Nov. 15, 2016 Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...